Form 4: Insmed CLO Michael Smith Executes Stock Sale

Insmed Incorporated Chief Legal Officer Michael Smith sold 6,149 shares of common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Michael Smith, Chief Legal Officer of Insmed Inc, sold 6,149 shares of common stock.
• The transaction occurred on May 22, 2026, at a price of $108.47 per share.
• Following the sale, the reporting person retains beneficial ownership of 41,613 shares.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 mechanism, which is standard practice for executive financial management.

Positives

• The transaction was conducted under a pre-established 10b5-1 trading plan, indicating the sale was planned in advance rather than based on immediate non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future share price appreciation, though this was a planned divestment.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard corporate practice for liquidity and diversification, and typically does not signal a change in company fundamentals.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives to sell shares while maintaining compliance with SEC insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Insmed, INSM, Insider Trading, Form 4, SEC Filing, Equity Sale